Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05316688 · ClinicalTrials.gov registry record · Phase 1
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
A Phase 1 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05316688 is a Phase 1 study that was terminated before completion, run by University of Washington. The registered enrollment target is 8 participants.
The verdict
NCT05316688, a Phase 1 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects of tozuleristide in imaging oral cavity squamous cell cancer and high-grade oral cavity dysplasia during surgery. Tozuleristide is an imaging agent that specifically binds to tumor cells. When exposed to near-infrared light, tozuleristide causes tumor cells to fluoresce (light up), so that surgeons may better distinguish tumor cells from healthy cells during surgery.
Interventions
- PROCEDURE Therapeutic Conventional Surgery
- PROCEDURE Near Infrared Imaging
- DRUG Tozuleristide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-04-17 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05316688
The ClinicalTrials.gov registry entry for NCT05316688 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Therapeutic Conventional Surgery is the first listed.
NCT05316688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05316688 about?
NCT05316688 is a clinical study titled "A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery". This phase I/II trial studies the side effects of tozuleristide in imaging oral cavity squamous cell cancer and high-grade oral cavity dysplasia during surgery. Tozuleristide is an imaging agent that specifically binds to tumor cells. When exposed to near-infrared light, tozuleristide causes tumor c...
What is the current status of trial NCT05316688?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-04-17. Estimated completion is 2025-09-26.
What interventions are being tested in trial NCT05316688?
The interventions under investigation include: Therapeutic Conventional Surgery (PROCEDURE), Near Infrared Imaging (PROCEDURE), Tozuleristide (DRUG).
Who is sponsoring clinical trial NCT05316688?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.